RAIN - Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting
NEWARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.
Presentation Title: |
Sustained disease control with MDM2 inhibitor milademetan in patients with advanced dedifferentiated liposarcoma |
Session: |
Session 3: Medical & Pediatric Oncology and Clinical Trials |
Presenter: |
Mrinal M. Gounder, M.D., Associate Attending Physician Memorial Sloan Kettering Cancer Center and Weill Cornall Medical Center, New York, NY, USA |
Session Date and Time: |
Thursday, November 17, 2022; 1:00-2:30 pm Pacific Time |
Location: |
VCC: East Exhibition Hall B |
A copy of the presentation materials can be accessed by visiting the " Resources ” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com